Biogen's Rituxan Label Expansion Delayed
Links shared publicly online about this topic.
- 1,588total visits
Biogen's Rituxan Label Expansion Delayed
Biogen's rituxan label expansion delayed-biogen works towards gaining final approval for the expanded indication and are planning to continue final label discussions with the fda
View full resource at zacks.com
Tags: Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, FDA, Rituxan
Most Recently Shared on November 20, 2009 at 5:09 pm By:
Rituxan shot down as part of first-line therapy for CLL http://bit.ly/8LKlRa
Advertisement
